NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Aclaris Therapeutics Inc (F: 8AT)

 
8AT Technical Analysis
5
As on 22nd Jan 2026 8AT STOCK Price closed @ 3.76 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.13 & Strong Buy for SHORT-TERM with Stoploss of 0.55 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

8ATSTOCK Price

Open 3.76 Change Price %
High 3.76 1 Day 0.13 3.58
Low 3.76 1 Week 1.50 66.37
Close 3.76 1 Month 1.52 67.86
Volume 1100 1 Year 1.52 67.86
52 Week High 3.76 | 52 Week Low 2.21
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
NT5 1000000.00 4629529.50%
NT5 1000000.00 4629529.50%
NT5 1000000.00 4629529.50%
30T 1000000.00 3759298.50%
 
F Germany Top Losers Stocks
PUB 0.00 -100.00%
PUB 0.00 -100.00%
PUB 0.00 -100.00%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
 
 
8AT
Daily Charts
8AT
Intraday Charts
Whats New @
Bazaartrend
8AT
Free Analysis
 
8AT Important Levels Intraday
RESISTANCE3.76
RESISTANCE3.76
RESISTANCE3.76
RESISTANCE3.76
RESISTANCE3.76
RESISTANCE3.76
RESISTANCE3.76
RESISTANCE3.76
 
8AT Forecast January 2026
4th UP Forecast6.79
3rd UP Forecast5.82
2nd UP Forecast5.22
1st UP Forecast4.62
1st DOWN Forecast2.9
2nd DOWN Forecast2.3
3rd DOWN Forecast1.7
4th DOWN Forecast0.73
 
8AT Weekly Forecast
4th UP Forecast6.79
3rd UP Forecast5.82
2nd UP Forecast5.22
1st UP Forecast4.62
1st DOWN Forecast2.90
2nd DOWN Forecast2.30
3rd DOWN Forecast1.70
4th DOWN Forecast0.73
 
8AT Forecast2026
4th UP Forecast6.79
3rd UP Forecast5.82
2nd UP Forecast5.22
1st UP Forecast4.62
1st DOWN Forecast2.9
2nd DOWN Forecast2.3
3rd DOWN Forecast1.7
4th DOWN Forecast0.73
 
 
8AT Other Details
Segment EQ
Market Capital 838042880.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
8AT Address
8AT
 
8AT Latest News
 
Your Comments and Response on Aclaris Therapeutics Inc
 
8AT Business Profile
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 640 Lee Road, Wayne, PA, United States, 19087
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service